ePrints

Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial (Nature Medicine, (2024), 10.1038/s41591-024-03282-2)

Lookup NU author(s): Sam SeeryORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024. Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03282-2, published online 1 October 2024. In the version of the article initially published, in Table 1, the “EO14” row was included in cohort B when it should have been part of cohort A. The amended table can now be found in the HTML and PDF versions of the article.

Publication metadata

Author(s): Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X

Publication type: Note

Publication status: Published

Journal: Nature Medicine

Year: 2025

Volume: 31

Print publication date: 01/01/2025

Online publication date: 16/10/2024

Acceptance date: 02/04/2024

ISSN (print): 1078-8956

ISSN (electronic): 1546-170X

Publisher: Nature Research

URL: https://doi.org/10.1038/s41591-024-03348-1

DOI: 10.1038/s41591-024-03348-1

PubMed id: 39415025

Share